FDA reviews peptide injections favored by RFK Jr. and wellness influencers
The Food and Drug Administration is hosting a two-day advisory meeting to evaluate the safety and clinical evidence behind several popular peptide injections. These substances have gained traction in the wellness industry for claims regarding injury recovery, muscle growth, and anti-aging effects. Despite this popularity among social media influencers and public figures like Health Secretary Robert F. Kennedy Jr., career scientists at the agency report a lack of rigorous data to support these benefits.
Regulators have expressed significant concerns regarding the quality control, contamination risks, and potential for allergic reactions associated with these compounds. Most existing research relies on animal studies rather than human clinical trials. Staffers at the agency have recommended against allowing these seven specific peptides to be added to the list of substances permitted for customized compounding by pharmacies. This stance aligns with warnings previously issued by the agency regarding substances such as BPC-157 and TB-500, both of which are classified as doping agents by international sports authorities.
The current advisory panel includes a mix of independent academics and individuals with financial ties to the peptide industry, including owners of wellness clinics and compounding pharmacies. This composition has raised questions about potential conflicts of interest as the group prepares to cast non-binding votes on whether these substances should be easier to access. While the agency has occasionally ignored expert panel recommendations, some legal observers suggest the eventual outcome may align with the push to expand access.
Public interest in this review remains high, with thousands of comments submitted to the agency. Proponents argue that enabling regulated pharmacies to compound these substances provides a safer alternative to the unregulated gray market. However, medical experts emphasize that the clinical evidence remains insufficient for widespread use. The agency will assess the meeting discussions and public input before determining the next steps for policy and enforcement regarding these injectables.